Perbak Capital Partners LLP Has $3.07 Million Stock Position in Illumina, Inc. $ILMN

Perbak Capital Partners LLP increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 79.5% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 32,315 shares of the life sciences company’s stock after purchasing an additional 14,315 shares during the period. Illumina makes up 0.5% of Perbak Capital Partners LLP’s holdings, making the stock its 19th biggest holding. Perbak Capital Partners LLP’s holdings in Illumina were worth $3,069,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ILMN. Quent Capital LLC acquired a new position in Illumina during the third quarter worth about $29,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Illumina in the 3rd quarter valued at approximately $33,000. Mather Group LLC. bought a new stake in shares of Illumina during the 3rd quarter valued at approximately $46,000. Evelyn Partners Investment Management LLP grew its holdings in shares of Illumina by 4,927.3% during the 2nd quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock valued at $49,000 after purchasing an additional 542 shares during the last quarter. Finally, SJS Investment Consulting Inc. increased its position in Illumina by 13,225.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 533 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 529 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on ILMN. Piper Sandler dropped their price objective on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. TD Cowen reiterated a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Evercore set a $150.00 price target on Illumina in a research note on Friday, February 6th. Stifel Nicolaus raised their price objective on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Finally, JPMorgan Chase & Co. reduced their price objective on Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $129.69.

Illumina Price Performance

ILMN stock opened at $118.94 on Friday. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. The firm has a market cap of $18.19 billion, a price-to-earnings ratio of 21.82, a PEG ratio of 2.21 and a beta of 1.45. The company’s fifty day simple moving average is $133.15 and its 200 day simple moving average is $119.81. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same period last year, the business posted $0.95 EPS. The business’s revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insider Buying and Selling

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.60% of the stock is owned by corporate insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.